Valneva (VALN) has released an update.
Valneva SE, a specialty vaccine company, has announced an Investor Day event to be held in New York on October 10, 2024, focusing on its innovative vaccine candidates for Lyme disease, Shigella, and Zika, as well as its commercial vaccine portfolio, including the only approved chikungunya vaccine. The event, which includes a live Q&A session with company executives, will be available both in person and via webcast. The company’s ongoing work is fueled by revenues from its commercial vaccines, with the goal of addressing significant unmet medical needs in infectious diseases.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
